Business
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients’ basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), known as the COMBAT-ALS study. These results were presented at the 36th International Symposium on ALS/MND, held Decem
About this update from Medicinova, Inc.
[{"type":"image","alt":"MediciNova, Inc.","displaySize":"","headline":null,"caption":"MediciNova, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/62db50f8b37ac476fe5ebe5e889fbeee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6DQPwj.XDP.I_St06Ug3kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/62db50f8b37ac476fe5ebe5e889fbeee","width":300,"height":106}},"lazy":false},{"type":"text","content":"LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients’ basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), known as the COMBAT-ALS study. These results were presented at the 36th International Symposium on ALS/MND, held December 5–7, 2025, in San Diego, California, USA.","length":545,"tagName":"p"},{"type":"text","content":"The poster presentation, titled “COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Basic Characteristics” (Reference # CTL-21), highlighted the following:","length":179,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Overview of the COMBAT-ALS Clinical Trial: Purpose, scientific rationale for MN-166 in ALS treatment, study design, and key eligibility criteria.","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Study Update: A total of 234 participants were randomized, and enrollment was completed in September 2025.","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Baseline Characteristics:","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total randomized patients: 234 (Female: 86 [36.8%], Male: 148 [63.2%])","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Mean age at screening: 60.6 years","length":33,"tagName":"p"}]},{"val":[{"type":"text","content":"Racial distribution: Caucasian (90.2%), Asian (5.1%), African American (1.3%), Native Hawaiian or Other Pacific Islander (0.4%), American Indian or Alaskan Native (0.4%), Other (2.6%)","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"A...